AR017884A1 - Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion - Google Patents

Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion

Info

Publication number
AR017884A1
AR017884A1 ARP980106440A ARP980106440A AR017884A1 AR 017884 A1 AR017884 A1 AR 017884A1 AR P980106440 A ARP980106440 A AR P980106440A AR P980106440 A ARP980106440 A AR P980106440A AR 017884 A1 AR017884 A1 AR 017884A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
prepare
treat patients
lacomposition
pellets
Prior art date
Application number
ARP980106440A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR017884A1 publication Critical patent/AR017884A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se provee una composicion farmacéutica que comprende una pluralidad de pellets, comprendiendo cada uno de dichos pellets un nucleo, una capa que rodeadicho nucleo, conteniendo dicha capa zafirlukast amorfo sustancialmente libre de otras formas físicas, y opcionalmente, otros ingredientes farmacéuticamenteaceptables; y un proceso para preparar la composicion; y un método para tratar pacientes usando la composicion. El proceso forma pellets adecuados paraespolvorear alimentos y bebidas.
ARP980106440A 1997-12-18 1998-12-17 Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion AR017884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726735.5A GB9726735D0 (en) 1997-12-18 1997-12-18 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AR017884A1 true AR017884A1 (es) 2001-10-24

Family

ID=10823809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106440A AR017884A1 (es) 1997-12-18 1998-12-17 Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion

Country Status (30)

Country Link
US (1) US6399104B1 (es)
EP (1) EP1041966B1 (es)
JP (1) JP2001526206A (es)
KR (1) KR20010033206A (es)
CN (1) CN1282244A (es)
AR (1) AR017884A1 (es)
AT (1) ATE243999T1 (es)
AU (1) AU744326C (es)
BR (1) BR9813666A (es)
CA (1) CA2313163A1 (es)
DE (1) DE69816124T2 (es)
DK (1) DK1041966T3 (es)
EE (1) EE04260B1 (es)
ES (1) ES2202915T3 (es)
GB (1) GB9726735D0 (es)
HU (1) HUP0004669A3 (es)
ID (1) ID25857A (es)
IL (1) IL136501A0 (es)
IN (1) IN191311B (es)
MY (1) MY133096A (es)
NO (1) NO20003141L (es)
NZ (1) NZ504566A (es)
PL (1) PL341736A1 (es)
PT (1) PT1041966E (es)
RU (1) RU2205006C2 (es)
SK (1) SK9402000A3 (es)
TR (1) TR200001713T2 (es)
UA (1) UA62991C2 (es)
WO (1) WO1999032082A2 (es)
ZA (1) ZA9811532B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO319624B1 (no) 2003-09-15 2005-09-05 Trouw Internat Bv Fiskefôr for laksefisk i ferskvann og anvendelse av slikt fôr.
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
CA2684655A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
CN107714694A (zh) * 2017-11-01 2018-02-23 天津国际生物医药联合研究院 扎鲁司特在抗结核分枝杆菌感染中的应用
CA3219671A1 (en) 2021-05-19 2022-11-24 Thomas Christian Lines Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
EP1041966A2 (en) 2000-10-11
KR20010033206A (ko) 2001-04-25
NO20003141D0 (no) 2000-06-16
WO1999032082A3 (en) 1999-09-16
EE200000330A (et) 2001-08-15
WO1999032082A2 (en) 1999-07-01
UA62991C2 (en) 2004-01-15
IL136501A0 (en) 2001-06-14
BR9813666A (pt) 2000-10-10
CN1282244A (zh) 2001-01-31
SK9402000A3 (en) 2001-01-18
DE69816124D1 (de) 2003-08-07
NZ504566A (en) 2002-10-25
MY133096A (en) 2007-10-31
ZA9811532B (en) 1999-06-18
JP2001526206A (ja) 2001-12-18
EP1041966B1 (en) 2003-07-02
DK1041966T3 (da) 2003-10-06
EE04260B1 (et) 2004-04-15
AU1571199A (en) 1999-07-12
PT1041966E (pt) 2003-11-28
CA2313163A1 (en) 1999-07-01
HUP0004669A3 (en) 2005-03-29
AU744326B2 (en) 2002-02-21
ATE243999T1 (de) 2003-07-15
DE69816124T2 (de) 2004-05-06
ES2202915T3 (es) 2004-04-01
AU744326C (en) 2002-11-07
TR200001713T2 (tr) 2000-10-23
GB9726735D0 (en) 1998-02-18
NO20003141L (no) 2000-06-16
IN191311B (es) 2003-11-22
PL341736A1 (en) 2001-05-07
HUP0004669A1 (hu) 2001-08-28
ID25857A (id) 2000-11-09
RU2205006C2 (ru) 2003-05-27
US6399104B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
ES2161574B1 (es) Granulos entericos de fluoxetina.
PL401469A1 (pl) Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja
AR017884A1 (es) Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
ATE68969T1 (de) Im magen verbleibende granula.
DE602005003343D1 (de) Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
HUP0300722A2 (hu) Hidrogél segítségével szabályozott gyógyszerforma
ES2157297T3 (es) Granulos entericos de duloxetina.
HK1049630A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same.
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
ES2172744T3 (es) Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
AR042517A1 (es) Un nucleo absorbente para usar en un articulo absorbente y el proceso para hacer dicho nucleo
UY24436A1 (es) Formulaciones orales de paroxetina de liberación controlada y retardada
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
NO20012985L (no) Anvendelse av apomorfin i fremstilling av et medikament for behandling av organisk erektil dysfunksjon i hanner
DE3681021D1 (de) Arzneimittelzubereitung mit verzoegerter freisetzung.
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ID30562A (id) Senyawa-senyawa amina aromatik tersubstitusi ribosa baru, metode pembuatannya dan penggunaannya sebagai obat
PL371382A1 (en) Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
ID29871A (id) Turunan-turunan morfolin baru, metode pembuatannya dan komposisi-komposisi farmasi yang mengandungnya
HK1047547A1 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
NO20001846D0 (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal